Highest-materiality recent filing
All seven incumbent directors re-elected; Daniel O'Connor received 5,130,879 votes withheld vs. ~200,000 for others.
DiaMedica Q1 net loss $10M; cash $51.3M; ReMEDy2 >70% enrollment
Net loss $10.0M in Q1 2026 vs $7.7M in Q1 2025; R&D expenses up to $8.0M from $5.7M.
DiaMedica reports FY2025 cash $59.9M; ReMEDy2 trial nearing 70% interim enrollment
Cash and investments $59.9M at Dec 31, 2025, up from $44.1M; runway through 2H 2027.
DiaMedica raises $12.2M via block sale of 1.5M shares at $8.10 under ATM
Sold 1,501,000 common shares to a healthcare institution fund on Dec 19, 2025.
FDA requested one non-clinical 10-day rabbit EFD/PPND study; results expected by Q2 2026.
DiaMedica Q3 net loss $8.6M; ReMEDy2 trial at 50% enrollment
Net loss $8.6M in Q3 2025, up from $6.3M a year ago; R&D expense $6.4M, up from $5.0M.
Phase 2 Part 1a interim data (n=28) showed statistically significant reductions in blood pressure and uterine artery pulsatility index with no placental transfer of DM199.
DiaMedica enters $100M ATM equity distribution agreement with TD Cowen
Up to $100M in common shares may be sold through TD Cowen as sales agent.
DiaMedica CMO Lorianne Masuoka resigns; Julie Krop appointed as successor
Lorianne Masuoka resigned as CMO effective Aug 4, 2025 for personal reasons; separation agreement provides health benefits through Oct 2026.
DiaMedica raises $30.1M via private placement of 8.6M shares at $3.50 to fund preeclampsia pipeline
Private placement of 8,606,426 common shares at $3.50 per share, raising $30.1M gross proceeds.
DiaMedica reports positive Phase 2 preeclampsia data: BP reductions, no placental transfer
DM199 highest dose (Cohort 9, n=3): SBP -35 mmHg (p<0.05), DBP -15 mmHg (p<0.05) at 5 min post-infusion.
DiaMedica shareholders elect all 7 director nominees, ratify auditor, approve say-on-pay
Michael Giuffre, Rick Kuntz, Tanya Lewis, Daniel O'Connor, James Parsons, Rick Pauls, Charles Semba elected with 96.3% or more of votes cast.
DiaMedica reports Q1 net loss $7.7M; preeclampsia Phase 2 topline data expected June-July 2025
Net loss $7.7M ($0.18/sh) vs $5.2M ($0.14) in Q1 2024; R&D expense rose to $5.7M on trial expansion.
DiaMedica FY2024 net loss $24.4M; cash $44.1M; preeclampsia data Q2 2025
Net loss $24.4M ($0.60/sh) vs $19.4M; R&D $19.1M, G&A $7.6M; no revenue.
Director Richard Pilnik to retire from DiaMedica board at 2025 AGM
Richard Pilnik, director for over 15 years, will retire and not stand for re-election at the 2025 AGM, effective May 15, 2025.
DiaMedica Therapeutics appoints Daniel J. O'Connor to Board of Directors
Daniel J. O'Connor appointed to Board effective Feb 20, 2025; joins Audit and Nominating & Corporate Governance Committees.
DiaMedica updates AIS trial protocol, delays interim readout to Q4 2025; Q3 R&D spend rises
Expanded ReMEDy2 trial to include thrombolytic non-responders; interim analysis sample size increased to 200 from 144.
DiaMedica updates on ReMEDy2 trial, starts preeclampsia study, extends cash to Q3 2026
ReMEDy2 AIS interim analysis enrollment (n=144) targeted for Q1 2025; 15 top U.S. centers prioritized.
DiaMedica Expands DM199 into Preeclampsia with Phase 2 Trial Starting Q4 2024
Phase 2 open-label, single-arm, investigator-sponsored trial enrolling up to 120 preeclampsia/FGR patients; first subject Q4 2024, topline results H1 2025.
DiaMedica raises $11.8M in private placement at $2.50/share; funds stroke and preeclampsia trials
Gross proceeds $11.8M from sale of 4.72M shares at $2.50/share; expected close June 28, 2024.
DiaMedica shareholders approve 3M share increase to 2019 Omnibus Incentive Plan
Shareholders approved amendment to increase shares available under 2019 Omnibus Incentive Plan by 3,000,000 shares.
DiaMedica dosed first patient in ReMEDy2 stroke trial; Q1 cash $46.5M
First participant enrolled in relaunched ReMEDy2 Phase 2/3 trial of DM199 for acute ischemic stroke.
Julie VanOrsdel Daves resigns as SVP, Clinical Development Operations effective April 18, 2024 for personal reasons.
DiaMedica FY2023: $52.9M cash, ReMEDy2 interim enrollment Q1 2025, CMO hired
Cash and investments $52.9M at Dec 31, 2023, up from $33.5M; net cash used in ops $18.7M.
DiaMedica amends ReMEDy2 stroke trial protocol; cash $56.2M with runway to 2026
FDA 30-day review of protocol amendments passed without comment; changes focus on moderate anterior circulation strokes (NIHSS 5-15).
CMO Kirsten Gruis resigns; interim CMO Jordan Dubow appointed for stroke trial
CMO Kirsten Gruis resigned effective Aug 31, 2023; she will consult for 9 months at $33,500/month.
DiaMedica Therapeutics Q2 2023: clinical hold lifted, $37.5M private placement, cash $60.7M
FDA fully lifted clinical hold on ReMEDy2 Phase 2/3 trial of DM199 for acute ischemic stroke on June 21, 2023.
FDA lifts clinical hold on DiaMedica's DM199 phase 2/3 stroke trial; resumption planned
FDA removed clinical hold on ReMEDy2 trial studying DM199 for acute ischemic stroke.
FDA lifts clinical hold on DiaMedica's DM199 acute ischemic stroke trial
FDA removed clinical hold on IND for DM199 phase 2/3 ReMEDy2 trial in acute ischemic stroke.
DiaMedica raises $37.5M in private placement; FDA lifts clinical hold on ReMEDy2 stroke trial
Raised $37.5M gross via 11,011,406 common shares at $3.40 each; management paid $3.91/share.
DiaMedica appoints former Medtronic CMO Richard Kuntz to Board of Directors
Dr. Kuntz appointed effective May 30, 2023; he recently retired as Medtronic's Chief Medical and Scientific Officer.
DiaMedica files clinical hold response with FDA for ReMEDy2 trial of DM199 in AIS
Filed complete clinical hold response with FDA on May 19, 2023 to lift hold on Phase 2/3 ReMEDy2 trial of DM199 for acute ischemic stroke.
Shareholders approved amendment to articles enhancing director nomination procedures referencing universal proxy rules with 4,520,227 votes for.
DiaMedica files clinical hold response; Q1 cash $28.7M; Phase 1C confirms DM199 dose safety
Company will file complete clinical hold response to FDA this week for ReMEDy2 AIS trial; in-use study supports dose revision to 0.5 µg/kg IV.
DiaMedica reports FY2022 cash $33.5M, updates on ReMEDy2 clinical hold progress
Cash and investments of $33.5M at Dec 31, 2022 vs $45.1M at end of 2021; cash runway into Q4 2024.
DiaMedica appoints Tanya N. Lewis to Board and Compensation Committee
Tanya N. Lewis appointed to DiaMedica Board effective March 1, 2023.
DiaMedica confirms no cash or securities at Silicon Valley Bank
Discloses it holds zero cash deposits or securities at Silicon Valley Bank.
DiaMedica appoints Tanya Lewis to board; Burroughs resigns
Amy L. Burroughs resigned as director effective March 1, 2023; no disagreement with company.
FDA maintains clinical hold on DM199 stroke trial; company to conduct additional IV stability study
FDA requires additional in-use in vitro stability study of IV administration of DM199 to resolve clinical hold on ReMEDy2 trial.
FDA maintains clinical hold on DiaMedica's ReMEDy2 stroke trial; cash $36.1M
FDA requires additional in-use IV stability study (tubing + pump) to lift clinical hold on Phase 2/3 ReMEDy2 trial.
DiaMedica identifies cause of DM199 clinical hold; plans FDA resubmission in Sep
Clinical hold cause: DM199 protein bound to prior IV bag, reducing dose; new bag delivered higher dose, causing hypotension.
FDA clinical hold on DiaMedica's ReMEDy2 trial for DM199 after 3 hypotension events
FDA placed clinical hold on Phase 2/3 ReMEDy2 trial of DM199 for acute ischemic stroke after 3 SAEs of transient hypotension.
DiaMedica Therapeutics subsidiary enters office lease for new headquarters in Minnetonka, MN
Lease for approx 6,175 sq ft at 301 Carlson Parkway, Suite 210, Minnetonka, MN.
Harry Alcorn, Jr., Pharm.D., SVP of Clinical Operations, resigned effective May 23, 2022.
Shareholders approved amendment to 2019 Omnibus Incentive Plan, increasing authorized shares by 2,000,000.
DiaMedica reports Q1 2022 cash burn of $3.9M; ReMEDy2 stroke trial sites more than double
Cash & investments $41M at March 31 (Dec 31: $45.1M); working capital $40.7M; cash runway into 2024.
DiaMedica reports 2021 results: $45M cash, Phase 2/3 stroke trial underway
Cash, cash equivalents and marketable securities $45.1M as of Dec 31, 2021; runway into 2024.
DiaMedica sets May 18, 2022 for annual meeting; shareholder proposal deadline March 4, 2022
Annual general meeting scheduled for May 18, 2022; date changed by more than 30 days from last year.
DiaMedica doses first patient in Phase 2/3 stroke trial; Q3 cash $48.1M after $30M raise
First patient dosed in pivotal ReMEDy2 trial of DM199 for acute ischemic stroke; ~350 patients planned.
DiaMedica raises $30M in private placement at $3.92/share for DM199 development
Gross proceeds of $30M from sale of 7,653,060 common shares at $3.92 each.
On February 28, 2025, Richard Pilnik, who has been a member of the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), for over 15 years, informed the Company of his decision to retire and not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”).
On February 20, 2025, the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel J. O’Connor to the Board, effective immediately.
Julie VanOrsdel Daves MSHS, CCRP notified us of her resignation as Senior Vice President, Clinical Development Operations of DiaMedica Therapeutics Inc. (“DiaMedica”), effective as of April 18, 2024, for personal reasons.
Following the departure of Ms. Daves, Rebekah de Vitry Fries, who currently serves as DiaMedica’s Vice President of Clinical Operations, will assume leadership of DiaMedica’s clinical operations.
On September 3, 2023, Kirsten Gruis, M.D. resigned from her position as Chief Medical Officer of DiaMedica Therapeutics Inc. (“DiaMedica” or the “Company”), effective as of August 31, 2023
To replace Dr. Gruis immediately on an interim basis while DiaMedica completes its search for a permanent Chief Medical Officer, DiaMedica has engaged as an independent consultant, Jordan Dubow, M.D.
On and effective March 9, 2023, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Ms. Lewis as a member of the Compensation Committee of the Board.
the Board of Directors (the “Board”) of the Company appointed Tanya N. Lewis to the Board, effective March 1, 2023.
To fill the vacancy created by Ms. Burroughs’s resignation, on March 1, 2023, the Company’s Board of Directors (the “Board”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Tanya N. Lewis to the Board, effective immediately, to fill the vacancy created by Ms. Burroughs’s resignation.
On March 1, 2023, Amy L. Burroughs resigned as a director of DiaMedica Therapeutics Inc.
On May 23, 2022, Harry Alcorn, Jr., Pharm.D., Senior Vice President of Clinical Operations of DiaMedica Therapeutics Inc. (the “Company”), resigned as an officer and employee of the Company and its subsidiaries, effective immediately.
the Company’s shareholders elected each of Amy Burroughs and Charles Semba, M.D. as a director of the Company effective immediately.
Max materiality 0.85 · Median 0.65 · Most common event other_material